RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)

Brief description of study

The main goal of this phase III clinical trial is to study how well erlotinib (an EGF receptor kinase inhibitor) with adjuvant therapy versus a placebo (an inactive drug) works in improving overall survival for patients with completely resected stage IB-IIIA EGFR mutant type non-small cell lung cancer


Clinical Study Identifier: s16-02079
ClinicalTrials.gov Identifier: NCT02193282
Principal Investigator: Elaine Shum
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.